BioPharma DiveOriginal article
FDA starts review of Roche’s multiple sclerosis pill
NDA FilingfenebrutinibPositive
AI Analysis
Summary
The FDA has initiated review of Roche's fenebrutinib, marking the first time the agency has accepted an application for a drug like fenebrutinib in two major forms of MS. However, safety concerns remain under scrutiny during the regulatory process.
Outcome Details
FDA has started review of fenebrutinib application for multiple sclerosis
Importance:6/10
Sentiment:
0.30
FDA reviewmultiple sclerosisregulatory milestonesafety concerns
Related Companies
Read the original article
Published by BioPharma Dive on September 30, 2026 3:54 PM